Johnson&Johnson CEO: Currently has no intention of producing weight loss drugs and focuses on expanding into fields such as neurology and oncology
我放心你带套猛
发表于 2023-12-6 09:51:55
265
0
0
Johnson&Johnson CEO Joaquin Duato stated at the company's Investor Day event on December 5th that the company currently has no plans to produce weight loss pills due to the intense competition in the market.
Du Anqing stated that Johnson&Johnson is focusing on expanding widely in fields such as neurology and oncology. Du Anqing said, "If Johnson&Johnson has the opportunity to stand out in the weight loss drug market through assets that complement the company's business, it may reconsider."
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Johnson&Johnson plans to acquire biotech company Proteology for $850 million
- Is Johnson&Johnson clearing Kenvue shares and withdrawing from the skincare and beauty industry a win-win situation or a last resort?
- Qiangsheng subsidiary responds to "shortage of focus in Daduo": the company faces supply pressure and challenges due to a significant increase in market demand
- Lilly: We have applied to the FDA for the weight loss drug Zepbound to treat sleep apnea, and it is expected to be approved as early as the end of the year
- Johnson&Johnson appoints Zhou Mintao as President of Medical Technology China
- Johnson&Johnson China completes business changes, with Song Weiqun stepping down as chairman
- Johnson&Johnson China CEO Song Weiqun steps down as Chairman of Johnson&Johnson China
- Novo Nordisk reaches settlement with Mylan Pharmaceuticals over patent dispute over weight loss drug Ozempic and Wegovy
- Citigroup raises Johnson&Johnson's target price from $180 to $185
- Johnson&Johnson China's multiple product lines have been exposed to layoffs! An employee reported a layoff scale of 20%
-
11월 14일, 세계예선 아시아지역 제3단계 C조 제5라운드, 중국남자축구는 바레인남자축구와 원정경기를 가졌다.축구 국가대표팀은 바레인을 1-0으로 꺾고 예선 2연승을 거두었다. 특히 이번 경기 국내 유일한 중계 ...- 我是来围观的逊
- 8 시간전
- Up
- Down
- Reply
- Favorite
-
계면신문기자 장우발 4분기의 영업수입이 하락한후 텐센트음악은 다시 성장으로 돌아왔다. 11월 12일, 텐센트음악은 최신 재보를 발표했다.2024년 9월 30일까지 이 회사의 3분기 총수입은 70억 2천만 위안으로 전년 ...- 勇敢的树袋熊1
- 그저께 15:27
- Up
- Down
- Reply
- Favorite
-
본사소식 (기자 원전새): 11월 14일, 다다그룹 (나스닥코드: DADA) 은 2024년 3분기 실적보고를 발표했다. 수치가 보여준데 따르면 고품질발전전략에 지속적으로 전념하고 사용자체험을 끊임없이 최적화하며 공급을 ...- 家养宠物繁殖
- 어제 15:21
- Up
- Down
- Reply
- Favorite
-
11월 12일 소식에 따르면 소식통에 따르면 아마존은 무료스트리밍서비스 Freevee를 페쇄하고 일부 종업원과 프로를 구독서비스 Prime Video로 이전할 계획이다. 올해 초 아마존이 내놓은 몇 편의 대형 드라마의 효 ...- 度素告
- 그저께 13:58
- Up
- Down
- Reply
- Favorite
